KEYTRUDA POWDER (pembrolizumab)
MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Indication
PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma
PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma refers to a biologically distinct, malignant epithelial neoplasm arising from the mucosal lining of the stomach or the gastroesophageal junction. Read more about PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma
3 drugs 1 manufacturers
Drugs that treat it
Common PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma therapies.
KEYTRUDA (pembrolizumab)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
KEYTRUDA QLEX (pembrolizumab-berahyaluronidase alfa-pmph)
ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+33
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma refers to a biologically distinct, malignant epithelial neoplasm arising from the mucosal lining of the stomach or the gastroesophageal junction.
Affecting the upper gastrointestinal system, this clinical state is defined by the concurrent overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2) alongside cellular expression of programmed death-ligand 1 (PD-L1), typically quantified by a combined positive score of 1 or greater.
Pathophysiologically, HER2 hyperactivation drives aggressive cellular proliferation and oncogenic signaling, while tumor and immune-cell PD-L1 expression mediates immune evasion via T-cell inhibition within the microenvironment.
In the locally advanced unresectable or metastatic setting, this biomarker-defined profile represents an aggressive gastrointestinal malignancy uniquely susceptible to dual targeting with anti-HER2 therapy and immune checkpoint inhibition.
- fda.gov
PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma refers to a biologically distinct, malignant epithelial neoplasm arising from the mucosal lining of the stomach or the gastroesophageal junction Affecting the upper gastrointestinal system, this clinical state is defined by the concurrent overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2) alongside cellular expression of programmed death-ligand 1 (PD-L1), typically quantified by a combi...
- cancer.gov
PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma refers to a biologically distinct, malignant epithelial neoplasm arising from the mucosal lining of the stomach or the gastroesophageal junction Affecting the upper gastrointestinal system, this clinical state is defined by the concurrent overexpression or gene amplification of human epidermal growth factor receptor 2 (HER2) alongside cellular expression of programmed death-ligand 1 (PD-L1), typically quantified by a combi...
Personalize your experience
Follow PD-L1+, HER2-positive gastric or gastroesophageal junction adenocarcinoma and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.